Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Hans Petter Eikesdal, Synnøve Yndestad, Ahmed El‐Zawahry, et al.
Annals of Oncology (2020) Vol. 32, Iss. 2, pp. 240-249
Open Access | Times Cited: 161

Showing 1-25 of 161 citing articles:

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 499
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi, Hope S. Rugo, Christian Jackisch
Targeted Oncology (2021) Vol. 16, Iss. 3, pp. 255-282
Open Access | Times Cited: 293
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1796-1796
Open Access | Times Cited: 121
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Paola Ferrari, Cristian Scatena, Matteo Ghilli, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1665-1665
Open Access | Times Cited: 100
PARP inhibition in breast cancer: progress made and future hopes
Nadine Tung, Judy E. Garber
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
Karama Asleh, Nazia Riaz, Torsten O. Nielsen
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 90
BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Xiaoyu Fu, Wei Phin Tan, Qibin Song, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 68
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Alba Llop‐Guevara, Sibylle Loibl, Guillermo Villacampa, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1590-1596
Open Access | Times Cited: 79
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara, et al.
Cancer Research (2022) Vol. 82, Iss. 8, pp. 1646-1657
Open Access | Times Cited: 64
Triple negative breast cancer: approved treatment options and their mechanisms of action
Aditya Mandapati, Kiven Erique Lukong
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 7, pp. 3701-3719
Open Access | Times Cited: 49
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Felipe Batalini, Niya Xiong, Nabihah Tayob, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 8, pp. 1493-1499
Open Access | Times Cited: 43
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
Xiaoxiang Sun, Huanyin Tang, Yu Chen, et al.
Nature Cancer (2023) Vol. 4, Iss. 5, pp. 716-733
Closed Access | Times Cited: 24
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, et al.
The Oncologist (2023) Vol. 28, Iss. 10, pp. 845-855
Open Access | Times Cited: 23
Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
Alexandre Bertucci, François Bertucci, Anthony Gonçalvès
Cancers (2023) Vol. 15, Iss. 5, pp. 1416-1416
Open Access | Times Cited: 22
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing
Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, et al.
Genes (2024) Vol. 15, Iss. 2, pp. 219-219
Open Access | Times Cited: 10
Tackling PARP inhibitor resistance
Kasper Fugger, Graeme Hewitt, Stephen C. West, et al.
Trends in cancer (2021) Vol. 7, Iss. 12, pp. 1102-1118
Closed Access | Times Cited: 42
Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
Per Eystein Lønning, Oleksii Nikolaienko, Kathy Pan, et al.
JAMA Oncology (2022) Vol. 8, Iss. 11, pp. 1579-1579
Open Access | Times Cited: 33
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
Hao Wen, Zheng Feng, Yutong Ma, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 32
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Maria Clara Saad Menezes, Farah Raheem, Lida A. Mina, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4332-4332
Open Access | Times Cited: 30
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Lin Wang, Dan Wang, Olmo Sonzogni, et al.
Cell Reports (2022) Vol. 41, Iss. 2, pp. 111462-111462
Open Access | Times Cited: 29
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Felipe Batalini, D. Gulhan, Victor Y. Mao, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4714-4723
Open Access | Times Cited: 28
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes BesidesBRCA1andBRCA2as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
Ioannis A. Voutsadakis, Athina Stravodimou
Anticancer Research (2023) Vol. 43, Iss. 3, pp. 967-981
Open Access | Times Cited: 17
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Banu K. Arun, Fergus J. Couch, Jean Abraham, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top